# Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

> **NCT00412594** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 150 (estimated)

## Conditions studied

- Hairy Cell Leukemia
- Recurrent Hairy Cell Leukemia

## Interventions

- **DRUG:** Cladribine
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT00412594
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2004-06-10
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00412594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00412594, "Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00412594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*